sellWeak cluster of 310b5-1 plan
Kavita Patel sold $95k of ACLX
director at Arcellx, Inc.. 1,500 shares at an average of $63.16, traded Feb 25, 2025, filed Feb 25, 2025.
Warning score
25Value
$95k
1,500 shares
Holdings after
0
-100% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleDirector
- +10Trade size$95k at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001415889-25-005594, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 25, 2025 | MOption exercise Common Stock10b5-1 | +1,500 | $6.66 | $9,990 | 1,500 | Feb 25, 2025 |
| Feb 25, 2025 | SOpen-market sale Common Stock10b5-1 | -1,500 | $63.16 | $95k | 0 | Feb 25, 2025 |
| Feb 25, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -1,500 | $0.00 | $0 | 34,577 | Feb 25, 2025 |
Related signals
Other insiders at Arcellx, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 38Weak | Arcellx, Inc. | Rami Elghandour SEE REMARKS | $10M 89,916 shares | -25% | |
| 45Moderate | Arcellx, Inc. | Michelle Gilson CHIEF FINANCIAL OFFICER | $1.3M 11,219 shares | -25% | |
| 39Weak | Arcellx, Inc. | Michelle Gilson CHIEF FINANCIAL OFFICER | $573k 8,384 shares | -16% | |
| 42Moderate | Arcellx, Inc. | Michelle Gilson CHIEF FINANCIAL OFFICER | $785k 11,291 shares | -17% | |
| 10Weak | Arcellx, Inc. | David Charles Lubner director | $450k 6,000 shares | -22% | |
| 29Weak | Arcellx, Inc. | Christopher Heery CHIEF MEDICAL OFFICER | $403k 5,882 shares | -20% | |
| 31Weak | Arcellx, Inc. | Christopher Heery CHIEF MEDICAL OFFICER | $487k 7,437 shares | -20% | |
| 29Weak | Arcellx, Inc. | Christopher Heery CHIEF MEDICAL OFFICER | $393k 6,131 shares | -14% | |
| 20Weak | Arcellx, Inc. | Christopher Heery CHIEF MEDICAL OFFICER | $31k 340 shares | -54% | |
| 30Weak | Arcellx, Inc. | Michelle Gilson CHIEF FINANCIAL OFFICER | $488k 5,364 shares | -39% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.